{
    "address": "Medicon Village, Scheeletorget 1",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W0166P109",
    "description": "Abliva AB engages in the research and development of pharmaceuticals that protect mitochondria from death post acute traumatic injury. The company is headquartered in Lund, Skane and currently employs 9 full-time employees. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.",
    "employeeTotal": "9.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2008-10-03",
    "isin": "SE0002575340",
    "logo": "",
    "marketCapitalization": 274.0446,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Abliva AB",
    "phone": "46462756220.0",
    "sedol": "B3CL8Y1",
    "shareOutstanding": 296.340132,
    "state": "SKANE",
    "ticker": "ABLI.ST",
    "weburl": "http://abliva.com/"
}